Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Yuzbashian E, Asghari G, Mirmiran P, Hosseini FS, Azizi F
No indefinite medication dependence With GLP-1 drugs, continued success often depends on continued treatment
By the end of the week, thirteen companies had launched twenty-six brands
R14 A blood pressure goal 40%, progression to dialysis or renal death), with HR 0.82 95% CI of 0.730.93, p = 0.001 and number needed to treat (NNT) of 29 patients, in addition to lower incidence of secondary cardiovascular outcome (cardiovascular death, AMI, non-fatal stroke, hospitalization for heart failure), HR 0.86 95% CI 0.750.99, p = 0.03 and NNT of 42
US$ 22.77
US$ 22.77
US$ 25.52
US$ 26.37
